Preventive therapies targeting calcitonin gene-related peptide (CGRP)—ie, monoclonal anti-CGRP or anti-CGRP receptor antibodies, which are injected subcutaneously or intravenously, and gepants, which are given orally—have substantially improved therapeutic options and provided relief for many people with migraine. These new therapies offer superior efficacy compared with traditional migraine treatments, as shown in a systematic review and network meta-analysis.1 However, not all patients respond to therapies targeting the CGRP pathway and alternative biological targets are still under investigation.